What Crystal Pharmatech does

Crystal Pharmatech is a privately held, China-incorporated global CRO and CDMO founded in 2010 that specializes in solid-state research and advanced formulation development for small molecule drugs. The company serves pharmaceutical and biotechnology companies across the development lifecycle — from early developability assessment through API form selection, crystallization development, pre-formulation, formulation development, GMP clinical and commercial manufacturing, and clinical supply — under its proprietary Mol2Med™ First-Time-Right 3-STEP methodology. It has expanded into adjacent modalities via the Crystal Bio Solutions division (biologics characterization, bioanalytical services, quantitative clinical pharmacology) and the Crystal NAX division (DNA/RNA synthesis, LNP formulation, and early-phase manufacturing for nucleic acid therapeutics). Core technology differentiators include the MicroED platform (first dedicated deployment in Asia-Pacific via partnership with ELDICO Scientific), an OEB4/OEB5 high-potency laboratory, spray drying and hot-melt extrusion capabilities for amorphous solid dispersions, pediatric mini-tablet technology, and the Molecule-Material-Medicine formulation strategy.

The company operates four R&D centers spanning Cranbury (New Jersey, two sites), Pleasanton (California), Mississauga (Toronto, Canada), and Suzhou (China headquarters and GMP manufacturing in Biobay), with a combined R&D and GMP footprint of 519,090 ft² and approximately 300 employees globally. Revenue is generated through project-based CRO and CDMO contracts — including managed services for GMP manufacturing — with multi-year contract cadences and quote-based pricing tied to project scope and complexity. Distribution is direct via business development teams in the US, Canada, and China; the company does not use third-party resellers.

Crystal Pharmatech has served over 2,000 clients and completed over 4,000 projects, including work for 8 of the 10 largest multinational pharmaceutical companies, with a track record of 100+ New Chemical Entities delivered and 15 commercial drug products supported. Its customer base spans large multinational pharma, mid-sized pharma, biotechs, virtual pharma, startups, and non-profit organizations. Multi-jurisdiction regulatory credentials — GMP/GDP certification by SGS, EU QP audit pass, China Drug Product Manufacturing License, CNAS reaccreditation, and US client remote audit pass — enable cross-border clinical and commercial supply.

Name

Crystal Pharmatech

Legal name

Crystal Pharmatech Co., Ltd.

Website

https://crystalpharmatech.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Crystal Pharmatech is a global CRO/CDMO founded in 2010, providing solid-state research, formulation development, and GMP manufacturing services for small molecule, biologic, and nucleic acid therapeutics to pharmaceutical and biotechnology companies across the US, Canada, and China.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research and Manufacturing (CRO/CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Solid-State Chemistry & Preformulation (Polymorph/Crystallization) (HLAGAHAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Contract research organization
• Solid-state characterization
• Formulation development services
• Pharmaceutical CDMO services
• Drug development research

Headquarters

HQ city

Cranbury, New Jersey

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CRO Services: Contract research organization services including solid-state research, polymorph/salt/co-crystal screening, crystallization development, pre-formulation studies, and analytical services. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.
2. CDMO Manufacturing Services: Contract development and manufacturing organization services including clinical and commercial manufacturing, GMP production, and clinical supply. Revenue generated through manufacturing service contracts with cGMP facilities.
3. Biologics and Nucleic Acid Services: Through Crystal Bio Solutions and Crystal NAX divisions, providing biologics characterization, bioanalytical services, quantitative clinical pharmacology, DNA/RNA synthesis, and LNP formulation services

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Crystal Pharmatech operates as a contract research and contract development organization (CRO/CDMO) providing solid-state research, preformulation, formulation development, and GMP manufacturing services for small molecule pharmaceutical compounds. The company supports drug developers across solid form selection, crystallization process development, and finished dosage form manufacturing using proprietary platforms such as Mol2Med and a MicroED-based single crystal structure analysis platform.

Product overview

Crystal Pharmatech operates as a global contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering an integrated portfolio of pharmaceutical development services. The company's core offering is the proprietary Mol2Med™ First-Time-Right 3-STEP Approach, a unified methodology that guides clients from early molecule evaluation through clinical manufacturing. The service portfolio spans three main divisions: Small Molecule services (including developability assessment, API form and solid-state research, crystallization development, pre-formulation studies, analytical research, formulation development, and GMP clinical/commercial manufacturing), Crystal Bio Solutions (biologics characterization, bioanalytical services, and quantitative clinical pharmacology), and Crystal NAX (DNA/RNA synthesis, LNP formulation, and early-phase manufacturing for nucleic acid therapeutics). Supporting these are technology platforms for oral dosage forms, including conventional formulations, enabling/bioavailability enhancement technologies for insoluble drugs and PROTACs, and pediatric mini-tablet formulations. The company has also developed advanced capabilities including a dedicated MicroED platform for absolute structure determination and an OEB4/OEB5 high-potency laboratory for handling highly potent compounds.

Differentiator

Problem solved

Functional benefit

Brands

• Crystal Bio Solutions: Biologics characterization, CMC analytics, bioanalytical and biomarker services, and quantitative clinical pharmacology.
• Crystal NAX
• Crystal Formulation Services
• Mol2Med™

Products and services

• Solid-State Research and Solid Form Selection Services

Quantifiable outcome

• Solid form screening and crystallization of over 2,000 drug molecules over 12 years
• +3 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core, strategic and regulatory.

• ELDICO ScientificcoreTechnology or Integration · 1 April 2026Crystal Pharmatech became the first company in Asia-Pacific to deploy a dedicated MicroED platform through strategic collaboration with ELDICO Scientific. This partnership enables advanced absolute structure determination and crystal identification capabilities for sub-micron crystals, significantly enhancing their solid-state characterization services.
• Particle SciencescoreStrategic or Co-development PartnerUS-China pharmaceutical CRO partnership formed to provide integrated cross-border services combining Particle Sciences' formulation expertise with Crystal Pharmatech's solid-state research capabilities.
• XceleronstrategicStrategic or Co-development PartnerPartnership to improve early clinical development utilizing absolute bioavailability trials and solid-state solutions. Combines Xceleron's pharmacokinetic expertise with Crystal Pharmatech's solid-state characterization capabilities.
• DivamicsstrategicStrategic or Co-development PartnerStrategic collaboration to accelerate drug development through AI, crystal form, and formulation innovation. Integrates Divamics' AI capabilities with Crystal Pharmatech's crystal form and formulation expertise.
• CATUGstrategicStrategic or Co-development PartnerCATUG and Crystal Bio established strategic partnership launching the CATUG-Crystal Joint Lab dedicated to advanced nucleic acid analytical services, combining expertise in nucleic acid therapeutics development.
• SGSregulatoryOthersCrystal Formulation Services successfully passed dual certification of GMP and GDP conducted by SGS, an international testing, inspection, and certification company. SGS provides regulatory auditing and certification services.

Scale indicators12 records

Recent moves10 records

Expansion highlights7 records

Broad incumbents

• Lonza: Lonza is one of the world's largest CDMOs with API, formulation, and biologics manufacturing at global scale. Competes for the same large pharma outsourcing budgets and represents a major benchmark peer for capacity, capabilities, and regulatory footprint.
• Catalent: Catalent is a major global CDMO offering formulation, softgel, biologics, and clinical supply across hundreds of programs. Broad incumbent with overlapping capabilities but much larger scale and breadth than Crystal Pharmatech.
• Patheon (Thermo Fisher Scientific): Patheon, integrated into Thermo Fisher's pharma services, is a top global CDMO with API, oral solid dose, sterile, and biologics capabilities. Represents the broader commercial CDMO peer set for Crystal Pharmatech's drug product CDMO offering.
• Eurofins Scientific: Eurofins operates a global Discovery/CRO business including solid-state characterization, formulation support, and analytical services. Broad incumbent with overlapping specialty CRO capabilities that compete for outsourced pharma R&D budgets.

Direct peers

• Syngene International: Syngene is an India-headquartered integrated CRO/CDMO providing drug substance, formulation development, and GMP manufacturing — serving global pharma with similar scale, cost base, and scope to Crystal Pharmatech.
• Pharmaron: Pharmaron is a China-based integrated CRO/CDMO with formulation development, GMP manufacturing, and discovery services. Geographic and operational peer with broader scope than Crystal Pharmatech.
• Sai Life Sciences: Sai Life Sciences is an India-based CRO/CDMO offering formulation development, analytical services, and GMP manufacturing for small molecules. It targets similar global pharma clients and competes in enabling formulation and CDMO services for poorly soluble compounds.
• Solvias: Solvias is a Swiss-based CRO/CDMO with deep specialization in solid-state chemistry, polymorphism, salt/co-crystal screening, and formulation development for small molecules — directly comparable to Crystal Pharmatech's core Mol2Med workflow. It is one of the closest functional analogs in the solid-state CRO space.
• Almac Group: Almac is a UK/Northern Ireland-headquartered CDMO with strong formulation development, pre-formulation, and GMP manufacturing services for small molecule drug products — overlaps closely with Crystal's formulation and clinical supply offering.
• WuXi AppTec (WuXi STA): WuXi STA is a leading China-based CDMO with integrated API development, solid-state research, formulation, and GMP manufacturing. Most direct geographic and operational peer to Crystal Pharmatech, with substantially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/crystal-pharmatech

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crystal Pharmatech